RO7502175
- Generic Name
- RO7502175
- Drug Type
- Biotech
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7502175 as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors
Phase 1
Recruiting
- Conditions
- Locally Advanced or Metastatic Solid TumorsNSCLCHNSCCMelanomaTNBCEsophageal CancerGastric CancerCervical CancerColorectal CancerUrothelial Carcinoma
- Interventions
- First Posted Date
- 2022-10-14
- Last Posted Date
- 2025-04-25
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 450
- Registration Number
- NCT05581004
- Locations
- 🇳🇱
Het Nederlands Kanker Instituut Antoni Van Leeuwenhoek Ziekenhuis, Amsterdam, Netherlands
🇳🇱Universitair Medisch Centrum Groningen, Groningen, Netherlands
🇺🇸Florida Cancer Specialists - Sarasota, Sarasota, Florida, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath